

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

The information set out below in this announcement is provided for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company.



China Medical & HealthCare Group Limited

(Incorporated in Bermuda with limited liability)

(Stock Code: 383)

APPOINTMENT OF INDEPENDENT FINANCIAL ADVISER

Reference is made to the announcement jointly issued by the Fareast Global Limited, Tian An China Investments Company Limited, Allied Group Limited and China Medical & HealthCare Group Limited (the “**Company**”) on 16 June 2023 (as supplemented by the clarification announcement dated 19 June 2023) (the “**Announcements**”), in relation to, among other matters, the CMH Offer. Capitalised terms used herein shall have the same meanings as those defined in the Announcements unless the context requires otherwise.

The Company wishes to announce that Pelican Financial Limited (“**Pelican**”) has been appointed as the independent financial adviser to advise the CMH Independent Board Committee pursuant to Rule 2.1 of the Takeovers Code as to whether the terms of the CMH Offer are fair and reasonable and as to the acceptance of the CMH Offer (the “**Appointment**”). Pelican is a licensed corporation to carry out Type 6 (advising on corporate finance) regulated activities under the SFO.

The Appointment has been approved by the CMH Independent Board Committee, comprising Mr. Gao Zhaoyuan, a non-executive director of CMH, and Mr. Zhang Jian and Dr. Xia Xiaoning, the independent non-executive directors of CMH, which has been established to make recommendation to the CMH Independent Shareholders in relation to the CMH Offer pursuant to Rule 2.1 of the Takeovers Code.

The letter of advice from Pelican and the recommendation from the CMH Independent Board Committee in respect of the CMH Offer will be included in the Composite Document relating to the CMH Offer.

The shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company. If the shareholders and potential investors of the Company are in any doubt about their position or as to the action they should take, they should consult their stockbroker, bank manager, solicitor or other professional advisers.

By Order of the Board
China Medical & HealthCare Group Limited
Chong Sok Un
Deputy Chairman

Hong Kong, 21 June 2023

As at the date of this announcement, the Board comprises:

Executive Directors

Ms. Chong Sok Un (Deputy Chairman), Mr. Kong Muk Yin, Mr. Guo Meibao and Mr. Zhou Haiying

Non-Executive Directors

Mr. Lai Hin Wing Henry Stephen and Mr. Gao Zhaoyuan

Independent Non-Executive Directors

Mr. Zhang Jian, Dr. Xia Xiaoning, Dr. Wong Wing Kuen, Albert and Ms. Yang Lai Sum, Lisa

The directors of the Company jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statements in this announcement misleading.